Alector, Inc. (NASDAQ:ALEC) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Alector, Inc. (NASDAQ:ALEC - Get Free Report) have earned an average rating of "Hold" from the seven ratings firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $4.00.

Separately, HC Wainwright boosted their target price on Alector from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, May 9th.

Institutional Investors Weigh In On Alector

Several large investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Alector during the first quarter valued at approximately $126,000. Acadian Asset Management LLC grew its stake in shares of Alector by 39.8% during the first quarter. Acadian Asset Management LLC now owns 1,440,661 shares of the company's stock valued at $1,768,000 after buying an additional 410,205 shares during the last quarter. Jane Street Group LLC grew its stake in Alector by 4.7% in the first quarter. Jane Street Group LLC now owns 256,551 shares of the company's stock worth $316,000 after purchasing an additional 11,618 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Alector by 25.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,334,032 shares of the company's stock worth $1,641,000 after purchasing an additional 274,341 shares in the last quarter. Finally, Almitas Capital LLC grew its stake in Alector by 12.9% in the first quarter. Almitas Capital LLC now owns 321,568 shares of the company's stock worth $396,000 after purchasing an additional 36,723 shares in the last quarter. 85.83% of the stock is owned by institutional investors.

Alector Price Performance

Shares of NASDAQ:ALEC traded up $0.13 during mid-day trading on Wednesday, reaching $1.65. The stock had a trading volume of 565,311 shares, compared to its average volume of 835,947. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.10. The company has a market cap of $164.98 million, a P/E ratio of -1.31 and a beta of 0.74. Alector has a 1 year low of $0.87 and a 1 year high of $6.78. The business's 50 day moving average price is $1.36 and its 200 day moving average price is $1.46.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.